Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study seeks to find the 'Sweet Spot' for prostate surgery success

NCT ID NCT07591688

Knowledge-focused Sponsor: Ondokuz Mayıs University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 400 men undergoing HoLEP surgery for an enlarged prostate to see if the percentage of tissue removed (enucleation ratio) predicts how much their symptoms improve after 3 months. Researchers aim to find the minimum ratio needed for meaningful relief, measured by a standard symptom score. The results could help surgeons tailor the procedure for better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help surgeons determine the minimum amount of prostate tissue to remove for reliable symptom improvement after HoLEP surgery.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may vary by surgeon technique and patient factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult males with moderate to severe lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO) who are scheduled to undergo holmium laser enucleation of the prostate (HoLEP) at participating urology centers across multiple institutions.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men aged 18 years pr older who are planned to undergo HoLEP. * Participants who are willing to give informed consent. * Participants who have moderate to severe LUTS (referring to IPSS score 8 points or more). * No history of previous prostate or urethral surgery. Exclusion Criteria: * Unwillingness to provide informed consent. * Unwillingness to provide contact information or unreachability during follow-up periods. * Incidental diagnosis of a urogenital malignancy requiring primary treatment after enrollment (e.g., bladder tumor, renal cell carcinoma, testicular tumor).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign prostate obstruction (BPO) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Benign prostate obstruction (BPO)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ondokuz Mayis University, Faculty of Medicine, Department of Urology

    Samsun, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.